A 68-year-old with type 2 diabetes sees the news flash and does the back-of-the-napkin math. The list price Medicare used for comparison was approximately $959 for a 30-day supply. Starting January 1, 2027, the published negotiated price for the semaglutide group that includes Ozempic is $274. She expects her pharmacy bill to fall by the same 71%. The balance may drop, but not necessarily by 71%.
The $274 figure is not a new national copay. Her cost still runs through the plan’s deductible, tier placement, cost-sharing formula, and approval rules. Medicare lowered the price feeding into that machinery. It did not remove the machinery.
What Medicare Actually Negotiated
Semaglutide was one of 15 drugs selected for Medicare’s second round of price negotiations. The $274 figure is the published 30-day Maximum Fair Price (MFP) for the group containing Ozempic, Rybelsus, and Wegovy. Exact prices vary among packages and strengths. For example, the Centers for Medicare & Medicaid Services (CMS) calculated an MFP of $276.78 for one commonly used Ozempic pen. The prices take effect January 1, 2027.
Medicare negotiated what the drug can cost inside the program. Her Part D plan still determines what comes out of her wallet. It is not automatically the amount handed to the pharmacist. Part D plans must place selected drugs with negotiated prices on their formularies. They can still assign copays or coinsurance, request prior approval, and use step therapy when clinically appropriate. CMS says it will review formularies for practices that undermine access, but the plans retain considerable control over how that access works.
Coverage Comes Before Price
For the woman in this example, Ozempic is prescribed for type 2 diabetes and runs through her Part D plan. The lower negotiated price can reduce her cost, particularly when the plan charges a percentage rather than a fixed copay. Her actual savings will not be clear until the plan publishes its 2027 benefits.
Wegovy follows a different path. Part D can cover it for medically accepted uses such as reducing cardiovascular risk in certain adults with established heart disease and overweight or obesity. Coverage and approval criteria still matter.
A separate wrinkle arrived in 2026. The Medicare GLP-1 Bridge offers certain qualifying beneficiaries access to Wegovy and several other weight-management drugs for $50 a month. That temporary program operates outside the ordinary Part D benefit and has been extended through December 31, 2027. Someone receiving Ozempic through Part D for diabetes generally follows the plan route instead.
The Part D Ceiling Still Matters
For prescriptions covered through Part D, the maximum deductible rises to $700 in 2027, although individual plans may charge less. Annual out-of-pocket spending on covered drugs is capped at $2,400. Once a beneficiary reaches that ceiling, covered prescriptions carry no additional cost-sharing for the rest of the year.
Neither a cash purchase nor the $50 GLP-1 Bridge copay counts toward that limit. For the woman taking Ozempic for diabetes, the useful number will be the copay or coinsurance shown by her specific Part D plan, not the $274 figure in Medicare’s announcement.
What to Do Before January 1, 2027
Three checks will reveal more than the price drop:
- Read the 2027 Annual Notice of Change. Find Ozempic’s tier, copay or coinsurance, prior-approval rules, and any step-therapy requirement.
- Compare plans during Medicare Open Enrollment. Enter the exact drug, dosage, and pharmacy into Medicare Plan Finder between October 15 and December 7. A lower MFP does not make every plan equally affordable.
- Confirm which coverage path applies. Diabetes treatment through Part D, a covered Wegovy use, and eligibility for the GLP-1 Bridge produce different prices at the same pharmacy.
Medicare negotiated the price upstream. Her Part D plan still calculates what reaches the counter.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks